Product category:
Clinical chemistry analysis
News Release from: Perkin Elmer LAS (UK) | Subject: Placental Protein 13 (PP13)
Edited by the Laboratorytalk Editorial
Team on 02 February 2006
Early identification of risk for
preeclampsia
PerkinElmer secures exclusive rights to Placental Protein 13 (PP13), a new prospective biomarker for identifying patients at risk for preeclampsia developed by Diagnostic Technologies (DTL)
PerkinElmer's ultimate goal is to provide an early marker for preeclampsia that will accelerate the identification of potential treatments at the onset of the disease process and allow healthcare professionals to better manage high-risk pregnancies Further testing of PP13 will determine whether it can detect the predisposition for preeclampsia to allow for such improved patient management
This article was originally published on Laboratorytalk on 19 Apr 2002 at 8.00am (UK)
Related stories
Probing the source of diabetes
Newly developed gene probes increase efficiency and speed of research in studies of type 1 (juvenile) diabetes, detecting the presence of alleles by hybridisation reaction
Manage the entire gene expression process
With microarray labs generating more than one million primary data points daily, this gene expression data management software could speed up actual gene and drug discovery
Preeclampsia affects 5-7percent of all pregnant women and represents a serious challenge for obstetricians and prenatal and diagnostic laboratories.
The threatening disorder can result in loss of life; blindness; motor and mental disorders or premature newborns; pregnancy hypertension; and kidney, liver and cardiovascular malfunctioning.
It is estimated that nearly US$30 billion is spent today in healthcare costs to treat women with preeclampsia and their newborns.
Further reading
Protein workstation details revealed
Claimed to be the first of its kind, this workstation fully automates the processing of microscope slide-based protein microarrays
More genes in human cDNA microarray
Human cDNA microarray system for researchers seeking access to premium gene content as well proprietary detection technology for ultra-sensitive gene expression results
"PerkinElmer is the market leader in prenatal risk assessment, and is committed to providing comprehensive maternal health solutions to protect at-risk women," said Robert Friel, president of PerkinElmer Life and Analytical Sciences.
"This new partnership with Diagnostic Technologies holds the promise to provide early identification of patients at risk for preeclampsia and facilitate the adoption of protective measures before complications develop".
Unlike other potential markers, detectable only a few weeks before clinical symptoms appear, the new PP13 marker appears to be manifested earlier in the pregnancy.
Preliminary research data shows that measuring PP13 in a blood sample during the routine prenatal testing in the first trimester might lead to as high as a 90 percent identification rate in women who are at risk.
In addition, PP13 appears to identify patients at risk for both forms of the disorder, including restricted fetal growth preeclampsia and normal fetal growth preeclampsia.
"According to CDC National Birth Statistics, preeclampsia is the second most frequent cause of maternal death during pregnancy," said Hamutal Meiri, CEO of Diagnostic Technologies.
"Our partnership with PerkinElmer will contribute to the effort to establish an important new marker for this disorder that could help raise the standard of care of maternal health during pregnancy".
"At present, there is no proven effective method for the prevention of preeclampsia, but there is some evidence that the prophylactic use of low-dose aspirin, starting from the first-trimester of pregnancy, could reduce the prevalence of the disease," said Kypros Nicolaides, director of the Fetal Medicine Foundation.
"The preliminary data on PP13 is encouraging.
"It is now necessary to validate that data and undertake a large screening study by maternal serum PP13 and uterine artery Doppler, and randomise women in the high-risk group to determine if early intervention can truly reduce the prevalence of the disease.".
• Perkin Elmer LAS (UK): contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
